Navigation Links
Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
Date:9/15/2008

SAN DIEGO, Sept. 15 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced today that it has revised the expected timing of its announcement of results for the CLIRS trial, the company's Phase III clinical trial of Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections.

Cadence is currently engaged in discussions with the U.S. Food and Drug Administration (FDA) regarding the statistical analysis plan for the CLIRS trial. These discussions, which are being conducted under a Special Protocol Assessment (SPA), must be completed prior to unblinding the data from the trial. As a result, Cadence has revised the expected timing of its announcement of results for the CLIRS trial from the fourth quarter of 2008 to the first quarter of 2009. If the trial is successful, Cadence continues to plan for submission of a New Drug Application (NDA) for Omigard in the second quarter of 2009.

About the CLIRS trial

The CLIRS trial, or Central Line Infection Reduction Study, is Cadence's confirmatory Phase III clinical trial of Omigard(TM) for the prevention of catheter-related infections. The CLIRS trial is a multi-center, randomized, evaluation committee-blinded study in patients whose medical condition requires a central venous catheter. The primary efficacy endpoint of the clinical trial is to evaluate whether Omigard is superior to 10% povidone-iodine in the prevention of local catheter-site infections. The CLIRS trial, which has completed enrollment of over 1,850 patients randomized to receive either Omigard or 10% povidone-iodine, is designed to have 80% power to detect significance at the 0.05 level. The CLIRS trial is being conducted under an SPA with th
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
2. Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update
3. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
4. VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
5. Unibioscreen and Drais Pharmaceuticals Partner to Develop and Commercialize UNBS 5162 for Treatment of Cancer
6. Vanda Pharmaceuticals Provides Update on Iloperidone
7. Cerimon Pharmaceuticals Announces Positive Results from a Phase II Clinical Study of Its Diclofenac Sodium Patch for Acute Pain
8. Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
9. Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
10. Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351
11. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Md. , Oct. 24, 2014  The ... highlighted the latest results achieved by ... system. The National Precursor Log ... at the point of sale and helps flag ... narcotics agents often set up NPLEx "watch lists" ...
(Date:10/25/2014)... 2014 In conjunction with DURECT Corporation,s (Nasdaq: ... press release, you are invited to listen to the ... internet on Monday, November 3, 2014 at 4:30 pm ... live audio webcast of the presentation will be available ... clicking "Investor Relations."  If you are unable to participate ...
(Date:10/25/2014)... 24, 2014 Best Practices designed the ... with a forum for sharing insights about the ... a mechanism for creating and sharing solutions through ... findings from the Medical Affairs Consortium survey. ... for the first roundtable of the 2014-2015 Medical ...
Breaking Medicine Technology:Kentucky's NPLEx Technology Making Significant Progress 2DURECT Corporation Invites You to Join its Third Quarter 2014 Earnings Conference Call 2Strong Participation in Best Practices' Medical Affairs Consortium Survey 2
... MYL ) today announced that its subsidiary Mylan Pharmaceuticals Inc. has ... mg/20 mg, 2.5 mg/40 mg, 5 mg/10 mg, 5 mg/20 mg, ... mg, 10 mg/40 mg and 10 mg/80 mg, the generic version ... treatment of hypertension. Caduet Tablets had U.S. sales ...
... Inc. reported today that it has completed enrollment in ... product expressing the neurturin (NRTN) gene for the treatment ... patients at 11 medical centers throughout the United States.  ... provide constant, sustained expression of neurturin (NRTN), a neurotrophic ...
Cached Medicine Technology:Ceregene Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinson's Disease 2Ceregene Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinson's Disease 3Ceregene Completes Enrollment of Second Phase 2 Study of CERE-120 for the Treatment of Parkinson's Disease 4
(Date:10/26/2014)... 2014 The “LoveHandle" was featured on ... Report, which features the latest and coolest technology products ... expert and technology reporter for NewsWatch, conducted the product ... phones off the ground. , According to eMarketer, US ... operating a mobile device, and that doesn’t include talking. ...
(Date:10/26/2014)... 26, 2014 Revenue Masters Cloud Contract ... user-friendly software recently launched. Cloud Contract Modeling™ ... rates, including bundled payments and government reimbursement. Instead of ... be automatically checked against the payer contract to ensure ... , Revenue Masters, LLC, is a healthcare revenue cycle ...
(Date:10/25/2014)... Triton Algae Innovations, ... Dr. Xun Wang has joined the firm as ... Triton has developed a patented synthetic biology platform for ... Dr. Wang, the platform uses algae to produce novel ... “Algae are unique because they can produce compounds that ...
(Date:10/25/2014)... CA (PRWEB) October 25, 2014 More ... annual President’s Circle Reception on Monday at the home ... accomplishments and hear from guest speaker Dr. Winifred Lender ... worlds. , Dr. Lender, a Santa Barbara psychologist, author ... challenges and benefits of living in the digital age. ...
(Date:10/25/2014)... Wisconsin (PRWEB) October 25, 2014 QueenBeeTickets.com ... for a great selection at affordable prices. Bob Seger ... Center Huntington Center and Nationwide Arena are going on ... , Click Here to browse the selection ... Band at QueenBeeTickets.com. , The famous singer is touring ...
Breaking Medicine News(10 mins):Health News:A New Method for Keeping Mobile Devices from Falling was Featured on NewsWatch Television on October 16, 2014 2Health News:Keeping Hospitals Doors Open with Affordable Software Now Available 2Health News:Keeping Hospitals Doors Open with Affordable Software Now Available 3Health News:Triton Algae Innovations Ltd. Names Dr. Xun Wang as President 2Health News:Triton Algae Innovations Ltd. Names Dr. Xun Wang as President 3Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 2Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 3Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 4Health News:QueenBeeTickets.com Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2
... HealthDay Reporter , WEDNESDAY, Aug. 25 (HealthDay News) -- ... massive egg recall due to salmonella contamination has probably made you ... But now some time has passed, and you,re starting to ... the eggs languishing in your fridge or are you inviting a ...
... HealthDay Reporter , WEDNESDAY, Aug. 25 (HealthDay News) -- If ... overindulgence can be easily worked off at the gym, think ... month,s worth of unhealthy living changes physiology, making piled-on fat ... can have later long-term effects," said study co-author Dr. Torbjorn ...
... physical and emotional problems a year after surgery than before ... the key findings of a research study of more than ... Surgery . Researchers from The Netherlands spoke to ... 54, who had undergone planned surgery, ranging from plastic surgery ...
... HealthDay Reporter , TUESDAY, Aug. 24 (HealthDay News) -- A ... death after taking the glucose-lowering diabetes drugs Avandia and Actos ... to numerous other studies that found that the risk was ... findings are, however, in line with some other previous studies, ...
... times could be cut by over one third and patients, ... approach to the triage process of sorting patients for ... International Journal of Six Sigma and Competitive Advantage ... Zarqa, Jordan and colleagues have turned to a design strategy ...
... Reporter , TUESDAY, Aug. 24 (HealthDay News) -- Pregnant ... should not worry that their use will cause birth ... of women develop herpes simplex during the first trimester ... antiviral drugs such as acyclovir (Zovirax), valacyclovir (Valtrex) and ...
Cached Medicine News:Health News:Are The Eggs in Your Fridge Safe to Eat? 2Health News:Are The Eggs in Your Fridge Safe to Eat? 3Health News:Are The Eggs in Your Fridge Safe to Eat? 4Health News:Short-Term Overeating Could Make Long-Term Weight Loss Tougher 2Health News:Up to 1 in 4 patients report more physical problems a year after surgery than before 2Health News:Heart Risks the Same With 2 Diabetes Drugs: Study 2Health News:Heart Risks the Same With 2 Diabetes Drugs: Study 3Health News:Engineering shorter wait times in the ER 2Health News:Herpes Drugs Won't Raise Birth Defect Risk, Study Finds 2Health News:Herpes Drugs Won't Raise Birth Defect Risk, Study Finds 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: